# DESCRIPTION

- claim priority to provisional applications

## FIELD OF THE INVENTION

- relate to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases

## BACKGROUND OF THE INVENTION

- describe Leishmania major and leishmaniasis

## SUMMARY OF THE INVENTION

- provide novel Leishmania cyclic nucleotide-specific phosphodiesterase polypeptides and nucleic acid molecules
- include antibodies that recognize and bind to LmPDE polypeptides
- encompass various nucleotide and amino acid sequences

## BRIEF DESCRIPTION OF THE DRAWINGS

- show deduced amino acid sequences of LmPDE-A, LmPDE-B1, and LmPDE-B2 polypeptides
- show DNA sequences for full-length genes of LmPDE-A, LmPDE-B1, and LmPDE-B2

## DEFINITIONS

- define amino acid sequence
- define antibody
- define antigenic determinant
- define antisense
- define biological sample
- define biologically active
- define catalytic domain
- define chimeric antibody
- define complementary
- define control cell
- define expression control sequence
- define fragment
- define humanized antibody

## DETAILED DESCRIPTION OF THE INVENTION

- introduce second messengers and their biological roles
- describe PDEs and their functions
- discuss diseases related to PDE activity

### Polypeptides of the Invention

- introduce LmPDE polypeptides from Leishmania major
- describe full-length and fragment forms of LmPDE polypeptides
- discuss variants and mutants of LmPDE polypeptides
- describe post-translational modifications of LmPDE polypeptides
- provide examples of isolated and purified LmPDE polypeptides

### Nucleic Acid Molecules of the Invention

- introduce LmPDE nucleic acid molecules
- describe full-length genes of LmPDE-A, LmPDE-B1, and LmPDE-B2
- provide nucleic acid molecules encoding LmPDE polypeptides
- discuss allelic forms of LmPDE nucleotide sequences
- describe polymorphic forms of LmPDE nucleotide sequences
- introduce codon-usage variants of LmPDE nucleotide sequences
- provide isolated and purified polynucleotides
- describe genomic, cDNA, ribozyme, and antisense molecules
- introduce nucleotide sequences that selectively hybridize to LmPDE nucleotide sequences
- discuss stringent hybridization conditions
- provide RNA molecules that encode LmPDE polypeptides
- describe derivative nucleic acid molecules

### Recombinant Nucleic Acid Molecules Encoding LmPDEs

- introduce recombinant nucleic acid molecules encoding LmPDE polypeptides

### Vectors Comprising Novel LmPDEs

- define recombinant molecules
- describe vector types for expression
- outline expression control elements
- discuss initiation signals for translation

### Host-Vector Systems Comprising LmPDEs

- introduce host-vector systems
- describe prokaryotic host cells
- describe eukaryotic host cells
- outline transformation methods
- discuss identification of transformed cells
- describe bacterial expression vectors
- outline yeast expression vectors
- describe plant expression vectors
- discuss insect and mammalian expression systems

### Antibodies Reactive Against LmPDE Polypeptides

- provide antibodies that bind to LmPDEs
- describe types of antibodies (polyclonal, monoclonal, chimeric, humanized)
- motivate therapeutic and diagnostic uses of antibodies
- define antibody fragments (Fab, F(abâ€²)2, Fv, single-chain antibodies)
- describe chimeric antibodies (human and non-human portions)
- describe humanized antibodies
- outline methods for preparing antibodies (immunization, fusion proteins, phage display)
- describe selection of specific regions of LmPDE protein for generating antibodies
- outline methods for conjugating therapeutic agents to antibodies

### Use of Antibodies Against LmPDEs

- describe use of antibodies to screen expression libraries
- describe use of antibodies to enrich or purify LmPDE polypeptides
- outline diagnostic uses of antibodies (quantitative determination, diagnostic imaging)

### Methods for Generating LmPDE Polypeptides

- describe methods for generating LmPDE polypeptides (chemical synthesis, recombinant methods)

### Screening for Compounds that Modulate LmPDE Activity/Expression

- introduce LmPDE polypeptides and their role in regulating cAMP levels
- motivate modulation of LmPDE activity and expression for therapeutic purposes
- describe screening methods for identifying compounds that bind to LmPDE polypeptides
- outline types of compounds that can be screened, including peptides and small organic molecules
- distinguish between randomly and rationally selected compounds
- describe rational selection methods, including computer modeling and searching techniques
- outline methods for identifying active site structures of LmPDE polypeptides
- describe computer-based modeling methods for identifying candidate modulating compounds
- outline methods for modifying known compounds to improve modulating effects
- describe in vitro assays for identifying compounds that modulate LmPDE activity and expression
- outline cell-based assays for identifying compounds that interact with LmPDE polypeptides
- describe in vivo assays for testing compounds in animal models of Leishmania infection
- outline types of LmPDE polypeptides that can be used in screening assays
- describe sources of cellular extracts that can be tested for binding with LmPDE polypeptides
- outline therapeutic potential of identified compounds for treating diseases associated with Leishmania infection
- formulate dosage for human use
- estimate therapeutically effective dose
- generate transgenic organisms
- produce PDE-deficient organisms
- generate organisms with LmPDE-encoding nucleic acid
- use transgenic organisms for various purposes
- discuss uses of LmPDE polypeptides
- monitor course of disease or disorder
- use nucleic acid molecules for diagnosis
- use nucleic acid molecules for isolating related sequences
- discuss various hybridization methods

## EXAMPLES

### Example 1

- identify cyclic nucleotide-specific phosphodiesterases

### Example 2

- design PCR primers
- clone and sequence novel genes
- analyze sequence identity
- identify conserved domains

### Example 3

- evaluate genomic organization

### Example 4

- produce transgenic yeast strain
- evaluate PDE activity

### Example 5

- prepare yeast lysates
- assay PDE activity
- evaluate inhibitor sensitivity
- determine KM values
- analyze specificity

### Example 6

- determine effect of PDE inhibitors
- evaluate IC50 values
- analyze cell proliferation
- support development of Leishmania-specific PDE inhibitors

